Skip to main content

Advertisement

Log in

Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers

  • Correspondence
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Baseline characteristics and 6-month survival of SR acute GVHD patients according to treatment.

References

  1. Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, et al. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transpl. 2020;26:845–54.

    Article  CAS  Google Scholar 

  2. Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005;106:1495–500.

    Article  CAS  Google Scholar 

  3. Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017;2:e89798.

    Article  Google Scholar 

  4. Ferrara JLM, Chaudhry MS. GVHD: biology matters. Blood Adv. 2018;2:3411–7.

    Article  CAS  Google Scholar 

  5. Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131:2846–55.

    Article  CAS  Google Scholar 

  6. Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131:2846–55. https://doi.org/10.1182/blood-2018-01-822957.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, et al. The MAGIC Algorithm Probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3:4034–42.

    Article  CAS  Google Scholar 

  8. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–22.

    Article  CAS  Google Scholar 

  9. Auletta JJ, Eid SK, Wuttisarnwattana P, Silva I, Metheny L, Keller MD, et al. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation. Stem Cells. 2015;33:601–14.

    Article  CAS  Google Scholar 

Download references

Funding

National Cancer Institute (P01CA039542 and P30CA196521), the Pediatric Cancer Foundation, and Mesoblast provided funding for this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to James L. M. Ferrara.

Ethics declarations

Competing interests

FS, JH, FG and EB are employees of Mesoblast. JEL and JLMF have received consulting fees from Mesoblast and royalties from a GVHD biomarker patent.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kasikis, S., Baez, J., Gandhi, I. et al. Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers. Bone Marrow Transplant 56, 2869–2870 (2021). https://doi.org/10.1038/s41409-021-01442-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01442-3

  • Springer Nature Limited

Navigation